NO20025630D0 - Anvendelse av (+)-alfa-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol eller dets prodrug ved behandling av symptomer pådemens og dopaminindusert psykose - Google Patents
Anvendelse av (+)-alfa-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol eller dets prodrug ved behandling av symptomer pådemens og dopaminindusert psykoseInfo
- Publication number
- NO20025630D0 NO20025630D0 NO20025630A NO20025630A NO20025630D0 NO 20025630 D0 NO20025630 D0 NO 20025630D0 NO 20025630 A NO20025630 A NO 20025630A NO 20025630 A NO20025630 A NO 20025630A NO 20025630 D0 NO20025630 D0 NO 20025630D0
- Authority
- NO
- Norway
- Prior art keywords
- dimethoxyphenyl
- dopamine
- dementia
- prodrug
- fluorophenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20694300P | 2000-05-25 | 2000-05-25 | |
PCT/US2001/016653 WO2001089498A2 (en) | 2000-05-25 | 2001-05-23 | USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20025630D0 true NO20025630D0 (no) | 2002-11-22 |
NO20025630L NO20025630L (no) | 2003-01-24 |
Family
ID=22768607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20025630A NO20025630L (no) | 2000-05-25 | 2002-11-22 | Anvendelse av (+)-alfa-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol eller dets prodrug ved behandling av symptomer pådemens og dopaminindusert psykose |
Country Status (20)
Country | Link |
---|---|
US (3) | US20020099076A1 (no) |
EP (1) | EP1289527B1 (no) |
JP (1) | JP2003535058A (no) |
KR (1) | KR100784655B1 (no) |
CN (1) | CN1436078A (no) |
AR (1) | AR029666A1 (no) |
AT (1) | ATE390134T1 (no) |
AU (2) | AU6484201A (no) |
BR (1) | BR0111102A (no) |
CA (1) | CA2410554C (no) |
DE (1) | DE60133385T2 (no) |
DK (1) | DK1289527T3 (no) |
ES (1) | ES2300333T3 (no) |
IL (1) | IL152908A0 (no) |
MX (1) | MXPA02011511A (no) |
NO (1) | NO20025630L (no) |
NZ (1) | NZ522659A (no) |
PT (1) | PT1289527E (no) |
TW (1) | TWI299001B (no) |
WO (1) | WO2001089498A2 (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004009586A1 (en) | 2002-07-19 | 2004-01-29 | Biovitrum Ab | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
ES2359725T3 (es) * | 2004-09-30 | 2011-05-26 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos. |
US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
DE102006040278A1 (de) * | 2006-08-21 | 2008-03-20 | Technische Universität Dresden | Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms |
PT3325444T (pt) | 2015-07-20 | 2021-09-22 | Acadia Pharm Inc | Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
WO2017172757A1 (en) * | 2016-03-29 | 2017-10-05 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169096A (en) * | 1985-07-02 | 1992-12-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl-piperidine-methanol derivatives |
US5021428A (en) | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
US4783471A (en) | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
US4912117A (en) | 1985-07-02 | 1990-03-27 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds |
US4877798A (en) | 1987-11-23 | 1989-10-31 | Merrell Dow Pharmaceuticals Inc. | Treatment of fibromyalgia |
DE3888340T2 (de) | 1988-01-21 | 1994-06-30 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. |
US5106855A (en) | 1989-12-20 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Method for the treatment of glaucoma |
WO1991018602A1 (en) * | 1990-06-01 | 1991-12-12 | Merrell Dow Pharmaceuticals Inc. | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL |
US6004980A (en) | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
FR2738819B1 (fr) * | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
EP0796619A1 (en) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
WO1999020315A1 (en) * | 1997-10-23 | 1999-04-29 | The Research Foundation Of State University Of New York | Methods of screening potential atypical antipsychotic drugs |
DK1105132T3 (da) | 1998-08-28 | 2003-11-24 | Aventis Pharma Inc | Anvendelse af R(+)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinemethanol til behandling af obstruktiv søvnapnø |
AU1083099A (en) * | 1998-10-14 | 2000-05-01 | Aventis Pharmaceuticals Inc. | Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1-(2-(4- fluorophenyl) ethyl)-4- piperidinemethanol and their use as prodrugs of the 5HT2A receptor antagonist MDL 110,907 |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
-
2001
- 2001-05-18 US US09/861,980 patent/US20020099076A1/en not_active Abandoned
- 2001-05-23 PT PT01939312T patent/PT1289527E/pt unknown
- 2001-05-23 ES ES01939312T patent/ES2300333T3/es not_active Expired - Lifetime
- 2001-05-23 MX MXPA02011511A patent/MXPA02011511A/es active IP Right Grant
- 2001-05-23 DK DK01939312T patent/DK1289527T3/da active
- 2001-05-23 WO PCT/US2001/016653 patent/WO2001089498A2/en active IP Right Grant
- 2001-05-23 NZ NZ522659A patent/NZ522659A/en unknown
- 2001-05-23 EP EP01939312A patent/EP1289527B1/en not_active Expired - Lifetime
- 2001-05-23 DE DE60133385T patent/DE60133385T2/de not_active Expired - Fee Related
- 2001-05-23 KR KR1020027015968A patent/KR100784655B1/ko not_active IP Right Cessation
- 2001-05-23 JP JP2001585743A patent/JP2003535058A/ja active Pending
- 2001-05-23 IL IL15290801A patent/IL152908A0/xx unknown
- 2001-05-23 TW TW090112318A patent/TWI299001B/zh not_active IP Right Cessation
- 2001-05-23 AU AU6484201A patent/AU6484201A/xx active Pending
- 2001-05-23 AU AU2001264842A patent/AU2001264842B2/en not_active Ceased
- 2001-05-23 BR BR0111102-7A patent/BR0111102A/pt not_active Application Discontinuation
- 2001-05-23 CA CA002410554A patent/CA2410554C/en not_active Expired - Fee Related
- 2001-05-23 CN CN01810983A patent/CN1436078A/zh active Pending
- 2001-05-23 AT AT01939312T patent/ATE390134T1/de not_active IP Right Cessation
- 2001-05-23 AR ARP010102464A patent/AR029666A1/es unknown
-
2002
- 2002-08-13 US US10/217,843 patent/US20030036553A1/en not_active Abandoned
- 2002-11-22 NO NO20025630A patent/NO20025630L/no not_active Application Discontinuation
-
2004
- 2004-05-03 US US10/838,035 patent/US7132433B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TWI299001B (en) | 2008-07-21 |
JP2003535058A (ja) | 2003-11-25 |
PL359176A1 (en) | 2004-08-23 |
ES2300333T3 (es) | 2008-06-16 |
NZ522659A (en) | 2004-06-25 |
US20040204457A1 (en) | 2004-10-14 |
DE60133385T2 (de) | 2009-04-23 |
AR029666A1 (es) | 2003-07-10 |
IL152908A0 (en) | 2003-06-24 |
EP1289527A2 (en) | 2003-03-12 |
BR0111102A (pt) | 2003-03-11 |
AU2001264842B2 (en) | 2005-01-27 |
CN1436078A (zh) | 2003-08-13 |
PT1289527E (pt) | 2008-05-13 |
AU6484201A (en) | 2001-12-03 |
NO20025630L (no) | 2003-01-24 |
WO2001089498A2 (en) | 2001-11-29 |
DE60133385D1 (de) | 2008-05-08 |
ATE390134T1 (de) | 2008-04-15 |
CA2410554A1 (en) | 2001-11-29 |
KR20030034078A (ko) | 2003-05-01 |
MXPA02011511A (es) | 2003-04-25 |
US20020099076A1 (en) | 2002-07-25 |
US20030036553A1 (en) | 2003-02-20 |
KR100784655B1 (ko) | 2007-12-12 |
EP1289527B1 (en) | 2008-03-26 |
WO2001089498A3 (en) | 2002-05-10 |
CA2410554C (en) | 2009-02-03 |
US7132433B2 (en) | 2006-11-07 |
DK1289527T3 (da) | 2008-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92550I2 (fr) | Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables | |
LU91888I2 (fr) | L'apixaban et ses sels pharmaceutiquement acceptables dans l'une quelconque des formes bénéficiant de la protection du brevet initial | |
IT1318649B1 (it) | Composizioni farmaceutiche per il trattamento di mucositi e stomatiti. | |
GB0101577D0 (en) | Compounds | |
NO20025630D0 (no) | Anvendelse av (+)-alfa-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol eller dets prodrug ved behandling av symptomer pådemens og dopaminindusert psykose | |
NO20024808L (no) | FremgangsmÕte ved syntesen av perindopril og farmasöytisk akseptable salter derav | |
AU2001272852A1 (en) | Composition for the treatment of migraine | |
NO20052699D0 (no) | 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser. | |
NO20043370L (no) | N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer | |
DK1296705T3 (da) | Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom | |
NO20033498D0 (no) | Fremgangsmåte for behandling og törking av trevirke | |
IL175983A0 (en) | Processes and intermediates for the preparation of (r) -??-(2,3 - dimethoxyphenyl) - 1 - [2 - (4-fluorophenyl) ethyl] - 4 - piperidine methanol | |
NO20023448L (no) | Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin | |
NO20020031D0 (no) | Dihydrobenzodiazepiner og deres anvendelse ved behandling av dyslipidemi | |
BR9708109A (pt) | Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinametanol no tratamento de distúrbios depressivos e distúrbios bipolares | |
NO20043029L (no) | Karboksamidinderivater og deres anvendelse ved behandling av vaskulaere sykdommer | |
NO20031108D0 (no) | Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet | |
PL364392A1 (en) | Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof | |
AU2002221566A1 (en) | Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders | |
ITMI20011032A0 (it) | Macchina foratrice e fresatrice particolarmente studiata per l'applicazione di ferramenta ed elementi di mobili | |
NO20053247L (no) | Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt. | |
HUP0202145A3 (en) | The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders | |
NO20011805L (no) | Estere av (+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol og deres anvendelse somprodrugs for 5HT2A reseptorantagonist MDL 110,907 | |
PT1451177E (pt) | Derivados substituídos de 2-pirrolidin-2-1l-1h-indole para o tratamento da enxaqueca. | |
IL189557A0 (en) | Combination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |